PMID- 11551425 OWN - NLM STAT- MEDLINE DCOM- 20011004 LR - 20221207 IS - 0169-5002 (Print) IS - 0169-5002 (Linking) VI - 33 IP - 2-3 DP - 2001 Aug-Sep TI - Radiation recall reaction following gemcitabine. PG - 299-302 AB - A case of dermatitis and myositis in the upper thorax following administration of gemcitabine in a 65-year-old woman with metastatic non small cell lung cancer (NSCLC) is described. The reaction and time course suggest a radiation recall phenomenon. This report joins a small but increasing number of radiation recall events related to gemcitabine. The possibility of a radiation recall reaction should be borne in mind when a patient develops symptoms in a previously irradiated site without evidence of disease progression at that site. Cessation of the precipitating drug is the most important step in management and systemic steroids may hasten symptomatic relief. FAU - Fogarty, G AU - Fogarty G AD - Division of Radiation Oncology, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne Vic., Australia. fogartygerald@petermac.unimelb.edu.au FAU - Ball, D AU - Ball D FAU - Rischin, D AU - Rischin D LA - eng PT - Case Reports PT - Journal Article PL - Ireland TA - Lung Cancer JT - Lung cancer (Amsterdam, Netherlands) JID - 8800805 RN - 0 (Radiation-Sensitizing Agents) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) SB - IM MH - Aged MH - Carcinoma, Non-Small-Cell Lung/radiotherapy/secondary MH - Deoxycytidine/*adverse effects/analogs & derivatives MH - Erythema/etiology MH - Female MH - Humans MH - Lung Neoplasms/pathology/radiotherapy MH - Myositis/*etiology MH - Radiation-Sensitizing Agents/*adverse effects MH - Radiodermatitis/*etiology MH - Gemcitabine EDAT- 2001/09/12 10:00 MHDA- 2001/10/05 10:01 CRDT- 2001/09/12 10:00 PHST- 2001/09/12 10:00 [pubmed] PHST- 2001/10/05 10:01 [medline] PHST- 2001/09/12 10:00 [entrez] AID - S0169500201001945 [pii] AID - 10.1016/s0169-5002(01)00194-5 [doi] PST - ppublish SO - Lung Cancer. 2001 Aug-Sep;33(2-3):299-302. doi: 10.1016/s0169-5002(01)00194-5.